Salvato P, Thompson C, Stroud S, Knight B, Carroll E; International Conference on AIDS.

Int Conf AIDS. 1992 Jul 19-24; 8: A76 (abstract no. PoA 2441).

Houston Immunological Institute, Texas.

OBJECTIVES: To determine if patients on Zidovudine (AZT) and Acyclovir combination therapy survive longer or progress slower in disease than patients on AZT alone. METHODS: CD4 counts of 100 HIV seropositive patients treated between November 1990 and January 1992 were analyzed. At baseline 48 patients had CD4 counts between 0-200, 32 had CD4 counts between 200-500, and 20 had CD4 counts greater than 500. All CD4 counts were measured by the same laboratory. Six (6) patients were not on antiviral therapy (mean CD4 = 596); 5 patients were on Acyclovir alone (mean CD4 = 810); 41 patients were on AZT alone (mean CD4 = 234); and 40 patients were on AZT/Acyclovir combination (mean CD4 = 252). Percent change in CD4 count was the outcome measure in a univariant ANOVA with medication type as the independent variable. RESULTS: At the end of 14 months, 68 patients were alive and 32 had died. Percent change in CD4 count was evaluable in 72 patients. ANOVA and Chi. Square analysis indicated that disease progression was a function of medication type. Results indicate that medication type significantly (p less than .0003) related to percent change in CD4 count and patient survival. Patients on Acyclovir or on no medication (CD4 count greater than 500) experienced an 8% increase in CD4 count. Patients on AZT alone experienced an average CD4 decrease of 60% while patients on AZT and Acyclovir experienced an average CD4 decrease of 34%. Forty-eight percent (48%) of patients on AZT alone survived while 88% on both AZT and Acyclovir survived. CONCLUSIONS: Recent reports indicate that Acyclovir in combination with AZT decreases the death rate associated with AIDS. Data from the current study provide support for the hypothesis that treatment with combination AZT/Acyclovir as compared to AZT alone significantly slows disease progression and increases survival in patients with HIV disease. TABULAR DATA, SEE ABSTRACT VOLUME.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Acyclovir
• Antigens, CD4
• Antiviral Agents
• CD4 Lymphocyte Count
• HIV Infections
• HIV Seropositivity
• Humans
• Zidovudine
• immunology
• therapy

Other ID:

• 92400759

UI: 102198472

From Meeting Abstracts